Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47,028 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Ravandi F, Jorgensen JL, Thomas DA, O'Brien S, Garris R, Faderl S, Huang X, Wen S, Burger JA, Ferrajoli A, Kebriaei P, Champlin RE, Estrov Z, Challagundla P, Wang SA, Luthra R, Cortes JE, Kantarjian HM. Ravandi F, et al. Among authors: huang x. Blood. 2013 Aug 15;122(7):1214-21. doi: 10.1182/blood-2012-11-466482. Epub 2013 Jul 8. Blood. 2013. PMID: 23836561 Free PMC article.
Eradication of minimal residual disease in hairy cell leukemia.
Ravandi F, Jorgensen JL, O'Brien SM, Verstovsek S, Koller CA, Faderl S, Giles FJ, Ferrajoli A, Wierda WG, Odinga S, Huang X, Thomas DA, Freireich EJ, Jones D, Keating MJ, Kantarjian HM. Ravandi F, et al. Among authors: huang x. Blood. 2006 Jun 15;107(12):4658-62. doi: 10.1182/blood-2005-11-4590. Epub 2006 Feb 23. Blood. 2006. PMID: 16497968 Free article. Clinical Trial.
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.
Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Kantarjian H, et al. Among authors: huang x. Blood. 2007 Jan 1;109(1):52-7. doi: 10.1182/blood-2006-05-021162. Epub 2006 Aug 1. Blood. 2007. PMID: 16882708 Free article. Clinical Trial.
Effect of haematological improvement on survival in patients given targeted therapy as initial treatment of acute myeloid leukaemia or high-risk myelodysplastic syndrome.
Yanada M, Huang X, Garcia-Manero G, O'brien S, Ravandi F, Borthakur G, Faderl S, Issa JP, Kantarjian H, Estey E. Yanada M, et al. Among authors: huang x. Br J Haematol. 2007 Aug;138(4):555-7. doi: 10.1111/j.1365-2141.2007.06670.x. Epub 2007 Jun 25. Br J Haematol. 2007. PMID: 17593249 Free article. No abstract available.
A prognostic score for patients with lower risk myelodysplastic syndrome.
Garcia-Manero G, Shan J, Faderl S, Cortes J, Ravandi F, Borthakur G, Wierda WG, Pierce S, Estey E, Liu J, Huang X, Kantarjian H. Garcia-Manero G, et al. Among authors: huang x. Leukemia. 2008 Mar;22(3):538-43. doi: 10.1038/sj.leu.2405070. Epub 2007 Dec 13. Leukemia. 2008. PMID: 18079733
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome.
Faderl S, Ravandi F, Huang X, Garcia-Manero G, Ferrajoli A, Estrov Z, Borthakur G, Verstovsek S, Thomas DA, Kwari M, Kantarjian HM. Faderl S, et al. Among authors: huang x. Blood. 2008 Sep 1;112(5):1638-45. doi: 10.1182/blood-2007-11-124602. Epub 2008 Jun 18. Blood. 2008. PMID: 18565853 Free PMC article. Clinical Trial.
47,028 results
You have reached the last available page of results. Please see the User Guide for more information.